# INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

> **NCT06144840** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 165 (actual)

## Conditions studied

- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)

## Interventions

- **DRUG:** Dersimelagon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06144840
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2026-04-14
- **Final completion:** 2026-06
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144840, "INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06144840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*